Dedham, MA, United States of America

Emile Farhan

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Mersana Therapeutics, Inc.. Active years: 2013.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emile Farhan: Innovator in Biodegradable Pharmaceutical Formulations

Introduction

Emile Farhan is a notable inventor based in Dedham, MA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly focusing on biodegradable biocompatible materials. His innovative work has the potential to impact drug delivery systems positively.

Latest Patents

Emile Farhan holds a patent for "Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates." This patent describes a camptothecin/polymer dual-phase drug release system that is stable in both liquid and lyophilized states. The polymer utilized in this formulation contains acetals and/or ketals, showcasing his expertise in creating advanced drug delivery mechanisms.

Career Highlights

Emile Farhan is currently associated with Mersana Therapeutics, Inc., where he continues to develop innovative pharmaceutical solutions. His work at Mersana Therapeutics emphasizes the importance of creating effective and safe drug delivery systems that can enhance patient outcomes.

Collaborations

Emile has collaborated with talented individuals such as Mao Yin and James Rolke. These partnerships have allowed him to leverage diverse expertise in the development of his innovative formulations.

Conclusion

Emile Farhan's contributions to the field of biodegradable pharmaceutical formulations highlight his role as a key innovator. His work not only advances drug delivery systems but also emphasizes the importance of biocompatibility in pharmaceutical applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…